Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants

키워드

참고문헌 (70)

1. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
2. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
3. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
4. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
5. Yoon CH, "Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation : comparison between patients with versus without stroke", Stroke, 45, pp.2983~2988 (2014)
6. Hori M, "Dabigatran versus warfarin : effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation", Stroke, 44, pp.1891~1896 (2013)
7. Wong KS, "Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial", Stroke, 45, pp.1739~1747 (2014)
8. Goto S, "Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia : a subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation(ARISTOTLE)trial", Am Heart J, 168, pp.303~309 (2014)
9. Shimada YJ, "Effects of regional differences in Asia on efficacy and safety of edoxaban compared with warfarin-insights from the ENGAGE AF-TIMI 48 trial", Circ J, 79, pp.2560~2567 (2015)
10. Diener HC, "Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke : a subgroup analysis of the RE-LY trial", Lancet Neurol, 9, pp.1157~1163 (2010)
11. Hankey GJ, "Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of ROCKET AF", Lancet Neurol, 11, pp.315~322 (2012)
12. Easton JD, "Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of the ARISTOTLE trial", Lancet Neurol, 11, pp.503~511 (2012)
13. Lip GY, "Non-vitamin k antagonist oral anticoagulants(NOACs)for stroke prevention in Asian patients with atrial fibrillation : time for a reappraisal", Int J Cardiol, 180, pp.246~254 (2015)
14. 방오영, "New Oral Anticoagulants May Be Particularly Useful for Asian Stroke Patients", 대한뇌졸중학회지, 16(2), pp.73~80 (2014), 대한뇌졸중학회[DOI]
15. Chiang CE, "Stroke prevention in atrial fibrillation : an Asian perspective", Thromb Haemost, 111, pp.789~797 (2014)
16. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
17. Wang KL, "Non-vitamin k antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation : meta-analysis", Stroke, 46, pp.2555~2561 (2015)
18. Le Heuzey JY, "The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation", Am J Cardiol, 105, pp.687~693 (2010)
19. )registry, "Am J Cardiol", 2012, 378~382
20. Gamra H, "Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: Insights from the international RealiseAF survey", Arch Cardiovasc Dis, 107, pp.77~87 (2014)
21. Oldgren J, "Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: The RE-LY atrial fibrillation registry", Circulation, 129, pp.1568~1576 (2014)
22. Akao M, "Current status of clinical background of patients with atrial fibrillation in a community-based survey : the Fushimi AF registry", J Cardiol, 61, pp.260~266 (2013)
23. Miyamoto K, "Effect of renal function on anticoagulation therapy in Asian patients", Circ J, 79, pp.2098~2099 (2015)
24. Toyoda K, "Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan : the SAMURAI-NVAF study", Int J Stroke, 10, pp.836~842 (2015)
25. Shen AY, "Racial", ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation, 2007, pp.50, 309~315
26. Koennecke HC, "Cerebral microbleeds on MRI: Prevalence, associations, and potential clinical implications", Neurology, 66, pp.165~171 (2006)
27. Bang OY, "Impact of metabolic syndrome on distribution of cervicocephalic atherosclerosis : data from a diverse race-ethnic group", J Neurol Sci, 284, pp.40~45 (2009)
28. Tsai CF, "Epidemiology of stroke and its subtypes in Chinese vs white populations : a systematic review", Neurology, 81, pp.264~272 (2013)
29. Lovelock CE, "Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies", Stroke, 41, pp.1222~1228 (2010)
30. Song TJ, "Association of cerebral microbleeds with mortality in stroke patients having atrial fibrillation", Neurology, 83, pp.1308~1315 (2014)
31. Akoudad S, "Use of coumarin anticoagulants and cerebral microbleeds in the general population", Stroke, 45, pp.3436~3439 (2014)
32. Fisher M, "MRI screening for chronic anticoagulation in atrial fibrillation", Front Neurol, 4, pp.137~ (2013)
33. Wang Z, "Cerebral microbleeds: is antithrombotic therapy safe to administer?", Stroke, 45, pp.2811~2817 (2014)
34. The Stroke Risk in Atrial Fibrillation Working Group, "Independent predictors of stroke in patients with atrial fibrillation: a systematic review", Neurology, 69, pp.546~554 (2007)
35. Azoulay L, "Initiation of warfarin in patients with atrial fibrillation : early effects on ischaemic strokes", Eur Heart J, 35, pp.1881~1887 (2014)
36. Yesel Kim, "Paradoxical Procoagulant Effect of Early Doses of Warfarin: Possible Role of Non-Vitamin K Oral Anticoagulant in Patients with Atrial Fibrillation-Related Stroke", 대한뇌졸중학회지, 17(2), pp.216~218 (2015), 대한뇌졸중학회
37. Hong KS, "Rationale and design of TRIPLE AXEL : trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation", Int J Stroke, 10, pp.128~133 (2015)
38. Kim SJ, "Is atrial fibrillation always a culprit of stroke in patients with atrial fibrillation plus stroke?", Cerebrovasc Dis, 36, pp.373~382 (2013)
39. Jeong WK, "Volume and morphology of left atrial appendage as determinants of stroke subtype in patients with atrial fibrillation", Heart Rhythm, 13, pp.820~827 (2016)
40. Ntaios G, "CHADS2, CHA2S2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation", Neurology, 80, pp.1009~1017 (2013)
41. Chua SK, "Use of CHADS2 and CHA2S2DS2-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from Taiwan acute coronary syndrome full spectrum registry", PLoS One, 9, pp.e111167~ (2014)
42. Kim YD, "Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation", Stroke, 42, pp.930~934 (2011)
43. Cha MJ, "Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2S2DS2-VASc scores", Eur J Neurol, 19, pp.473~479 (2012)
44. Siu CW, "Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong", Heart rhythm, 11, pp.1401~1408 (2014)
45. Komocsi A, "Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome : systematic review and meta-analysis of randomized controlled trials", Arch Intern Med, 172, pp.1537~1545 (2012)
46. Kaatz S, "Stroke prevention in patients with atrial fibrillation and renal dysfunction", Stroke, 45, pp.2497~2505 (2014)
47. Reinecke H, "Preventing stroke in patients with chronic kidney disease and atrial fibrillation : benefit and risks of old and new oral anticoagulants", Stroke, 44, pp.2935~2941 (2013)
48. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial", Eur Heart J, 33, pp.2821~2830 (2012)
49. Hori M, "Efficacy and safety of dabigatran etexilate vs. Warfarin in Asian RE-LY patients according to baseline renal function or CHADS2 score", Circ J, 79, pp.2138~2147 (2015)
50. Hart RG, "Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran : the RE-LY trial", Stroke, 43, pp.1511~1517 (2012)
51. Goodman SG, "Factors associated with major bleeding events : insights from the ROCKET AF trial(rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)", J Am Coll Cardiol, 63, pp.891~900 (2014)
52. Hylek EM, "Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes", J Am Coll Cardiol, 63, pp.2141~2147 (2014)
53. Piccini JP, "Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation", Circulation, 133, pp.352~360 (2016)
54. Dans AL, "Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy(RE-LY)trial", Circulation, 127, pp.634~640 (2013)
55. Hamatani Y, "Predictors for stroke and death in non-anticoagulated Asian patients with atrial fibrillation: The Fushimi AF registry", PLoS One, 10, pp.e0142394~ (2015)
56. Piccini JP, "Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) and ATRIA (anticoagulation and risk factors in atrial fibrillation) study cohorts", Circulation, 127, pp.224~232 (2013)
57. Kodani E, "Use of warfarin in elderly patients with non-valvular atrial fibrillation-subanalysis of the J-rhythm registry", Circ J, 79, pp.2345~2352 (2015)
58. Turagam MK, "Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions : focus on non-vitamin K antagonist oral anticoagulants", Clin Interv Aging, 10, pp.1431~1444 (2015)
59. Potpara TS, "Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk", Prog Cardiovasc Dis, 58, pp.177~194 (2015)
60. Verheugt FW, "Oral anticoagulants for stroke prevention in atrial fibrillation: Current status, special situations, and unmet needs", Lancet, 386, pp.303~310 (2015)
61. Lip GY, "‘Real-world’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey", Am J Med, 127, pp.519~529.e1 (2014)
62. Lopatowska P, "Do CHA2S2DS2-VASc and HAS-BLED scores influence ‘real-world’ anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre", Pharmacoepidemiol Drug Saf, 24, pp.1297~1303 (2015)
63. Hori M, "Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation: the J-ROCKET AF study", Circ J, 76, pp.2104~2111 (2012)
64. Tanigawa T, "Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation", Drug Metab Pharmacokinet, 28, pp.59~70 (2013)
65. Ruff CT, "Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial", Lancet, 385, pp.2288~2295 (2015)
66. Koretsune Y, "Short-term safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment", Circ J, 79, pp.1486~1495 (2015)
67. Graham DJ, "Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation", Circulation, 131, pp.157~164 (2015)
68. Chan YH, "Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation", Stroke, 47, pp.441~449 (2016)
69. Ogawa S, "The APHRS’s 2013 statement on antithrombotic therapy of patients with nonvalvularatrial fibrillation", J Arrhythmia, 29, pp.190~200 (2013)
70. Keun-Hwa Jung, "Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke", 대한뇌졸중학회지, 17(2), pp.210~215 (2015), 대한뇌졸중학회

관련 논문AI추천